Impact Biomedical (IBO) Interest Expenses (2022 - 2026)
Impact Biomedical's (IBO) quarterly Interest Expenses came in at $11.0 million in Q1 2026, up 760.84% YoY from $1.3 million in Q1 2025, and down 2.59% on a QoQ basis from $11.3 million in Q4 2025.
Impact Biomedical (IBO) Interest Expenses (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 5 years of Interest Expenses data on file, last reported at $11.0 million in Q1 2026.
- Quarterly Interest Expenses rose 760.84% year-over-year to $11.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.0 million (up 760.84% YoY) and the FY2025 annual result came in at $11.3 million, up 917.88% from the prior year.
- Interest Expenses retreated to $11.0 million in Q1 2026, from $11.3 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $11.3 million in Q4 2025 to a low of $92000.0 in Q3 2022.
- A 5-year average of $2.0 million and a median of $1.1 million in 2023 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2024 — Interest Expenses changed 0.0% — and 2025, when it jumped 4095.93%.
- Tracing IBO's Interest Expenses over 5 years: stood at $99000.0 in 2022, then increased by 26.26% to $125000.0 in 2023, then soared by 116.0% to $270000.0 in 2024, then jumped by 4095.93% to $11.3 million in 2025, then retreated by 2.59% to $11.0 million in 2026.
- The last three Interest Expenses figures came in at $11.0 million (Q1 2026), $11.3 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 | 67,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.40 Mn |
| Jun 30, 2026 | 11.40 Mn |
| Mar 31, 2026 | 11.04 Mn |
| Mar 31, 2026 | 11.04 Mn |
| Dec 31, 2025 | 11.33 Mn |
| Dec 31, 2025 | 11.33 Mn |
| Sep 30, 2025 | 1.13 Mn |
| Sep 30, 2025 | 1.13 Mn |
| Jun 30, 2025 | 1.28 Mn |
| Jun 30, 2025 | 1.28 Mn |
| Mar 31, 2025 | 1.28 Mn |
| Mar 31, 2025 | 1.28 Mn |
| Dec 31, 2024 | 270,000.00 |
| Dec 31, 2024 | 270,000.00 |
| Sep 30, 2024 | 1.11 Mn |
| Sep 30, 2024 | 1.11 Mn |
| Jun 30, 2024 | 1.11 Mn |
| Jun 30, 2024 | 1.11 Mn |
| Mar 31, 2024 | 1.11 Mn |
| Mar 31, 2024 | 1.11 Mn |